In 2020, Salama et al. published the results of the NCI-MATCH trial’s subprotocol H, which aimed to investigate the combination of dabrafenib and trametinib in patients with solid tumors, lymphomas, or multiple myeloma harboring a BRAF V600 mutation [102]. Here, BRAF is linked to plasma cell myeloma.